Category Archives: Pr Newswire

AsiaMedic launches customised AI virtual assistantwith Enterprise SG affiliated startup MIEA Health

WhatsApp integrated AI virtual assistant expected to reduce call handling time, enabling AsiaMedic to serve its customers more efficiently and effectively. SINGAPORE, Aug. 12, 2024 /PRNewswire/ — SGX Catalist-listed AsiaMedic Limited (the “Company” and together with its subsidiaries, the “Group“), a leading health screening provider in Singapore, has launched an AI virtual assistant on WhatsApp to […]

Hong Kong Disneyland Resort Unveils Expansion Plan for All-new Extended Marvel-themed Area

SINGAPORE, Aug. 11, 2024 /PRNewswire/ — The universe of Marvel stories continues at Hong Kong Disneyland Resort. Josh D’Amaro, Chairman of Disney Experiences, announced at D23: The Ultimate Disney Fan Event in Anaheim, California an extended Marvel-themed area featuring a new attraction at Hong Kong Disneyland Resort as part of its multi-year expansion. With the […]

Breaking Boundaries: Haivivi Innovates with BubblePal, Redefining Interactive Toys

SINGAPORE, Aug. 9, 2024 /PRNewswire/ — The AI toy startup Haivivi has launched BubblePal, a groundbreaking interactive toy powered by AIGC technology—the first of its kind worldwide. This innovative product harnesses advanced AI large language model(LLM) technology to enrich children’s development and provide emotional support. BubblePal excels in multi-character interactions and multilingual communication, setting a new standard […]

MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application

MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) — The Multidisciplinary Association for Psychedelic Studies (MAPS) is evaluating the path forward for safe, legal access to MDMA-assisted therapy following the announcement from Lykos Therapeutics that the potential approval […]

State Grid Changzhou Power Supply Company Develops Low-Voltage Generator Vehicle to Ensure Uninterrupted Power Supply

CHANGZHOU, China, Aug. 10, 2024 /PRNewswire/ — “Voltage and current outputs of the generator vehicle are normal, ensuring steady power supply to the low-voltage district!” On August 8, in the Liyang High-Tech Industrial Park, State Grid Changzhou Power Supply Company successfully utilized its innovatively developed low-voltage diesel generator vehicle for seamless grid integration, ensuring continuous […]

2024 China Tianjin Binhai New Area Talent Innovation and Entrepreneurship Competition (Overseas Competition) Singapore Division Finals to Begin Soon

Smart Binhai, Glorious Competition! SINGAPORE, Aug. 10, 2024 /PRNewswire/ — With the success of the Hong Kong SAR Final Round of the 2024 China Tianjin Binhai New Area Talent Innovation and Entrepreneurship Competition (Overseas Competition) on 17th July, the Finals of the Singapore Division is about to kick off on 15th August. As the gateway to […]

11,000 Global Financial Insurance Elites Converge in Kuala Lumpur. International Dragon Award IDA members share glorious moments

A grand celebration of insurance knowledge and honor, united in wisdom and glory. KUALA LUMPUR, Malaysia, Aug. 10, 2024 /PRNewswire/ — The 15th Worldwide Chinese Life Insurance Congress & 2024 IDA Annual Conference is being held at the Malaysia International Trade and Exhibition Centre (MITEC) from August 9 to 12, 2024. This year’s theme, “CHANGE […]

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) is disappointed in the decision made by the US Food and Drug Administration (USFDA) to request […]

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100. Supportive data from preclinical study in atherosclerosis, a common obesity-related metabolic complication, is expected to be available H2-2024. […]

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today […]